Genocea Biosciences, Inc.
GNCA
GNCA was delisted on the 2nd of June, 2022.
54 hedge funds and large institutions have $44.5M invested in Genocea Biosciences, Inc. in 2018 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 8 increasing their positions, 14 reducing their positions, and 26 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17% less funds holding
Funds holding: 65 → 54 (-11)
21% less capital invested
Capital invested by funds: $56.4M → $44.5M (-$11.9M)
42% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 26
43% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
+$3.3M |
| 2 |
Millennium Management
New York
|
+$798K |
| 3 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$375K |
| 4 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
+$267K |
| 5 |
BI
BVF Inc
San Francisco,
California
|
+$248K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.48M |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$616K |
| 3 |
State Street
Boston,
Massachusetts
|
-$565K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$509K |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
-$277K |
GNCA Hedge Fund Activity: Q2 2018 in Review
54 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q2 2018, worth a combined $44.5M — down 21% from $56.4M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of GNCA and 15 opened new positions — a net loss of 11 holders — while 14 trimmed existing stakes and 8 added.
The largest buyer was Ghost Tree Capital, opening a new position worth an estimated $3.3M. The largest seller was BlackRock, cutting an estimated $3.48M.
- 54 institutional investors held Genocea Biosciences, Inc. (GNCA) as of Q2 2018, down from 65 in Q1 2018.
- Funds reported $44.5M of Genocea Biosciences, Inc. stock for Q2 2018, down 21% quarter-over-quarter.
- 15 funds opened new Genocea Biosciences, Inc. positions in Q2 2018 and 26 closed out, a net change of -11 holders.
- The largest Genocea Biosciences, Inc. buyer in Q2 2018 was Ghost Tree Capital, an estimated $3.3M added.
- The largest Genocea Biosciences, Inc. seller in Q2 2018 was BlackRock, an estimated $3.48M sold.
Based on aggregated 13F filings for Q2 2018.